Stockscreener 앱 받기
117.62
0.15%
0.18
시간 외 거래:
117.62
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
Empowered Funds LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 11,502 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Impax Asset Management Group plc Raises Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
GSA Capital Partners LLP Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Boosted by Plato Investment Management Ltd - MarketBeat
Aigen Investment Management LP Purchases Shares of 5,948 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
(NBIX) Trading Report - Stock Traders Daily
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Strategic Sale: EIRY ROBERTS Decides To Exercise Options Worth $334K At Neurocrine Biosciences - Benzinga
Principal Financial Group Inc. Sells 120,576 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio - Benzinga
Neurocrine Biosciences: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
Why AbbVie’s disappointing schizophrenia drug trial bodes well for Bristol Myers - MarketWatch
How Neurocrine Biosciences helps health care professionals diagnose a movement disorder - Ad Age
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Earns "Hold" Rating from Needham & Company LLC - MarketBeat
Los Angeles Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Fiera Capital Corp Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels (NASDAQ:NBIX) - Seeking Alpha
Summit Global Investments Sells 24,024 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality - Yahoo Finance Australia
Beacon Harbor Wealth Advisors Inc. Buys Shares of 47,917 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Kornitzer Capital Management Inc. KS Makes New $3.59 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences presents new KINECT®-HD data showing consistent efficacy across 19 subgroups and improvements in aspects of emotional health with Ingrezza (valbenazine) capsules - PharmaLive
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Van ECK Associates Corp - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Nisa Investment Advisors LLC - MarketBeat
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.
Impax Asset Management Group plc Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Neurocrine Biosciences to Participate at Investor Conferences in November - PR Newswire
Neurocrine Biosciences' SWOT analysis: navigating challenges in a competitive biotech stock landscape - Investing.com
Positive results for Neurocrine’s Ingrezza in tardive dyskinesia - The Pharma Letter
AlphaCentric Advisors LLC Raises Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine (NBIX) to Present at 3 Major Healthcare Conferences in November | NBIX Stock News - StockTitan
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia - StockTitan
Cantor Fitzgerald Has Weak Estimate for NBIX FY2024 Earnings - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2024 Earnings Call Transcript - MSN
abrdn plc Sells 24,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine shares target upgraded, market perform rating on positive outlook By Investing.com - Investing.com Australia
Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from HC Wainwright - MarketBeat
Mirae Asset Global Investments Co. Ltd. Acquires 9,601 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Earnings call: Neurocrine Biosciences reports strong Q3 growth, plans ahead - Investing.com
Neurocrine: Q3 Earnings Snapshot - The Pioneer
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates - MSN
Neurocrine stock jumps 9% on strong Ingrezza sales, stock buyback - MSN
Forsta AP Fonden Sells 10,400 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap UpShould You Buy? - MarketBeat
Neurocrine Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
0.54%
1.33%
자본화:
|
볼륨(24시간):